D. Ramjit

发表

Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide: Comparison to Hirudin and Heparin in a Canine Model of Acute Coronary Artery Thrombosis

J. Lynch, I. I. Stabilito, G. Vlasuk, 1992, Circulation.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

J. Lynch, J. Cook, I. I. Stabilito, 1995, The Journal of pharmacology and experimental therapeutics.

Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment

R. Toto, L. Raij, S. Shahinfar, 1998 .

Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits

S. Gardell, J. Lynch, R. Shebuski, 1991, Circulation.

Vampire Bat Salivary Plasminogen Activator Evokes Minimal Bleeding Relative to Tissue-Type Plasminogen Activator as Assessed by a Rabbit Cuticle Bleeding Time Model

S. Gardell, J. Lynch, I. I. Stabilito, 1995, Thrombosis and Haemostasis.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

R. Gould, G. Hartman, N. Ihle, 1996, The Journal of pharmacology and experimental therapeutics.

Prevention of Canine Coronary Artery Thrombosis with Echistatin, a Potent Inhibitor of Platelet Aggregation from the Venom of the Viper, Echis carmatus

V. Garsky, P. Lumma, R. Shebuski, 1990, Thrombosis and Haemostasis.

Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.

J. Lynch, I. I. Stabilito, M. Holahan, 1993, The Journal of pharmacology and experimental therapeutics.

Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans.

M. Polokoff, R. Shebuski, G. Bencen, 1989, The Journal of biological chemistry.

Comparison of the In Vivo Anticoagulant Properties of Standard Heparin and the Highly Selective Factor Xa Inhibitors Antistasin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venous Thrombosis

C. Dunwiddie, D. Smith, R. Shebuski, 1991, Thrombosis and Haemostasis.

Pharmacokinetics, Safety, and Antihypertensive Efficacy of Losartan in Combination with Hydrochlorothiazide in Hypertensive Patients with Renal Impairment

S. Shahinfar, D. Snavely, M. Lo, 2003, Journal of clinical pharmacology.

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

B. Brenner, S. Shahinfar, Ronald D. Smith, 2002, Kidney international. Supplement.

Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group.

R. Toto, L. Raij, S. Shahinfar, 1998, Hypertension.

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

M. Schluchter, B. Brenner, J. McGill, 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

B. Brenner, J. Chan, G. Remuzzi, 2006, Kidney international.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

B. Brenner, D. de Zeeuw, S. Snapinn, 2005, Journal of the American Society of Nephrology : JASN.